The neurokinin-1 receptor modulates the methamphetamine-induced striatal apoptosis and nitric oxide formation in mice.
In a previous study we showed that pharmacological blockade of the neurokinin-1 receptors attenuated the methamphetamine (METH)-induced toxicity of the striatal dopamine terminals. In the present study we examined the role of the neurokinin-1 receptors on the METH-induced apoptosis of some striatal neurons. To that end, we administered a single injection of METH (30 mg/kg, i.p.) to male mice. METH induced the apoptosis (terminal deoxyncleotidyl transferase-mediated dUTP nick end labeling) of approximately 20% of striatal neurons. This percentage of METH-induced apoptosis was significantly attenuated by either a single injection of the neurokinin-1 receptor antagonist, 17-beta-hydroxy-17-a-ethynyl-5-a-androstano[3,2-beta]pyrimido[1,2-a]benzimidazole (WIN-51,708) (5 mg/kg, i.p.), or the ablation of the striatal interneurons expressing the neurokinin-1 receptors (cholinergic and somatostatin) with the selective neurotoxin [Sar(9),Met(O(2))(11)] substance P-saporin. Next we assessed the levels of striatal 3-nitrotyrosine (3-NT) by HPLC and immunohistochemistry. METH increased the levels of striatal 3-NT and this increase was attenuated by pre-treatment with WIN-51,708. Our data support the hypothesis that METH-induced striatal apoptosis occurs via a mechanism involving the neurokinin-1 receptors and the activation of nitric oxide synthesis. Our findings are relevant for the treatment of METH abuse and may be relevant to certain neurological disorders involving the dopaminergic circuitry of the basal ganglia.
Zhu
Judy
J
Department of Biological Sciences, Hunter College of the City University of New York, New York, New York, USA.
Xu
Wenjing
W
Wang
Jing
J
Ali
Syed F
SF
Angulo
Jesus A
JA
D000704:Analysis of Variance; D000731:Androstanes / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001562:Benzimidazoles / Q000494:pharmacology; D001831:Body Temperature / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004563:Electrochemistry / Q000379:methods; D000922:Immunotoxins / Q000494:pharmacology; D020287:In Situ Nick-End Labeling / Q000379:methods; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D008813:Mice, Inbred ICR; D008845:Microinjections / Q000379:methods; D009419:Nerve Tissue Proteins / Q000378:metabolism; D064729:Neurokinin-1 Receptor Antagonists; D009569:Nitric Oxide / Q000378:metabolism*; D018040:Receptors, Neurokinin-1 / Q000378:metabolism*; D054789:Ribosome Inactivating Proteins, Type 1 / Q000494:pharmacology; D000076985:Saporins; D013373:Substance P / Q000031:analogs & derivatives / Q000494:pharmacology; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism
D000731:Androstanes; D001562:Benzimidazoles; D000697:Central Nervous System Stimulants; D004338:Drug Combinations; D000922:Immunotoxins; D009419:Nerve Tissue Proteins; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D054789:Ribosome Inactivating Proteins, Type 1; C086111:WIN 51708; C062618:substance P, Sar(9)-Met(O2)(11)-; D009569:Nitric Oxide; D013373:Substance P; C002744:3-nitrotyrosine; D014443:Tyrosine; D008694:Methamphetamine; D000076985:Saporins
Nat Med. 1996 Jun;2(6):699-703
8640565
J Neurochem. 2004 Jan;88(1):114-23
14675155
J Pharmacol Exp Ther. 1986 Sep;238(3):932-7
2943891
Eur J Pharmacol. 1995 Sep 25;284(3):231-9
8666004
J Chem Neuroanat. 1996 Jun;10(3-4):179-90
8811421
Neuroscience. 2001;102(4):843-51
11182247
Synapse. 1998 Dec;30(4):433-45
9826235
J Pharmacol Exp Ther. 1991 Feb;256(2):506-12
1671596
J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
15163680
J Pharmacol Exp Ther. 1994 Aug;270(2):741-51
8071867
Prog Brain Res. 1998;118:3-11
9932430
Neuropharmacology. 2000 Jun 8;39(8):1337-56
10818251
J Neurochem. 2001 Feb;76(3):745-9
11158245
J Neurosci. 2004 Mar 31;24(13):3436-43
15056723
J Neurosci. 1997 Sep 15;17(18):6908-17
9278526
Brain Res Brain Res Rev. 1994 Jan;19(1):1-28
7909470
Neuropharmacology. 2002 Dec;43(8):1258-68
12527475
Inflamm Res. 2006 Jun;55(6):236-40
16955242
Synapse. 2005 Jul;57(1):1-7
15858838
Trends Neurosci. 1995 Dec;18(12):527-35
8638293
Brain Res. 2005 Jul 12;1049(2):171-81
16043139
Neuropharmacology. 1989 Oct;28(10):1145-50
2554183
J Neurosci. 1995 May;15(5 Pt 2):4102-8
7751968
Fed Proc. 1975 Aug;34(9):1823-31
1097267
Peptides. 1986 Nov-Dec;7(6):983-7
2436197
J Neurochem. 2008 Jul;106(2):696-705
18410508
J Subst Abuse Treat. 2002 Sep;23(2):151-6
12220613
Synapse. 2008 Mar;62(3):193-204
18081184
Neurology. 2000 Mar 28;54(6):1344-9
10746608
Behav Pharmacol. 2001 Nov;12(6-7):497-508
11742144
Synapse. 2005 Nov;58(2):110-21
16088948
J Pharmacol Exp Ther. 1998 Oct;287(1):107-14
9765328
J Neurochem. 1993 May;60(5):1792-9
8473897
Synapse. 1994 Jul;17(3):203-9
7974204
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5286-91
10220458
J Pharmacol Exp Ther. 1997 Aug;282(2):834-8
9262348
Brain Res. 1982 Mar 4;235(1):93-103
6145488
Arch Biochem Biophys. 1986 May 15;247(1):1-11
3010872
Brain Res. 2004 May 8;1007(1-2):124-31
15064143
Synapse. 2011 Apr;65(4):300-8
20730802
J Neurochem. 2002 Nov;83(3):613-22
12390523
Ann N Y Acad Sci. 1992 May 11;648:317-9
1637061
J Neurosci. 1998 Mar 15;18(6):1979-86
9482784
Am J Psychiatry. 2001 Mar;158(3):377-82
11229977
J Neurosci. 2003 Sep 10;23(23):8271-80
12967989
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5773-8
9576960
J Neurosci. 1995 Dec;15(12):8419-29
8613773
Science. 1998 Sep 11;281(5383):1640-5
9733503
J Pharmacol Exp Ther. 1979 Feb;208(2):203-9
762652
Synapse. 1996 Aug;23(4):328-34
8855518
J Neurochem. 1996 Oct;67(4):1770-3
8858965
J Neurochem. 2005 Apr;93(1):195-205
15773919
Neuroscience. 2006 Jun 30;140(2):607-22
16650608
Brain Res. 1980 Jul 7;193(1):153-63
7378814
Am J Psychiatry. 2001 Mar;158(3):383-9
11229978
Neurosci Lett. 1999 Dec 17;277(1):1-4
10643883
Brain Res. 1992 May 29;581(2):237-43
1356579
J Neurochem. 2001 Sep;78(5):952-9
11553669
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12096-101
10518582
J Neurosci. 1998 Oct 15;18(20):8417-22
9763484
Brain Res. 1984 Jun 15;303(2):359-64
6744029
J Pharmacol Exp Ther. 1985 Jun;233(3):539-44
2409267
Brain Res Mol Brain Res. 2001 Sep 10;93(1):64-9
11532339